<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="MicrobiolFront Cell Infect MicrobiolFront. Cell. Infect. Microbiol.Frontiers in Cellular and" exact="Infection" post="Microbiology2235-2988Frontiers Media S.A. pmcid: 7294848 doi: 10.3389/fcimb.2020.00317 : Cellular"/>
 <result pre="Microbiology2235-2988Frontiers Media S.A. pmcid: 7294848 doi: 10.3389/fcimb.2020.00317 : Cellular and" exact="Infection" post="Microbiology: Perspective ACE2, Much More Than Just a Receptor"/>
 <result pre="Host, a section of the journal Frontiers in Cellular and" exact="Infection" post="Microbiology epub: 2020-6-6collection: 2020pmc-release: 2020-6-610317received: 2020-4-22accepted: 2020-5-26(C) Samavati and"/>
 <result pre="with these terms. Abstract The rapidly evolving pandemic of severe" exact="acute" post="respiratory syndrome coronavirus (SARS-CoV-2) infection worldwide cost many lives."/>
 <result pre="these terms. Abstract The rapidly evolving pandemic of severe acute" exact="respiratory" post="syndrome coronavirus (SARS-CoV-2) infection worldwide cost many lives. The"/>
 <result pre="terms. Abstract The rapidly evolving pandemic of severe acute respiratory" exact="syndrome" post="coronavirus (SARS-CoV-2) infection worldwide cost many lives. The angiotensin"/>
 <result pre="rapidly evolving pandemic of severe acute respiratory syndrome coronavirus (SARS-CoV-2)" exact="infection" post="worldwide cost many lives. The angiotensin converting enzyme-2 (ACE-2)"/>
 <result pre="(ACE-2) has been identified as the receptor for the SARS-CoV-2" exact="viral" post="entry. As such, it is now receiving renewed attention"/>
 <result pre="therapeutics. We review the physiological functions of ACE2 in the" exact="cardiovascular" post="system and the lungs, and how the activation of"/>
 <result pre="the activation of ACE2/MAS/G protein coupled receptor contributes in reducing" exact="acute" post="injury and inhibiting fibrogenesis of the lungs and protecting"/>
 <result pre="injury and inhibiting fibrogenesis of the lungs and protecting the" exact="cardiovascular" post="system. In this perspective, we predominantly focus on the"/>
 <result pre="this perspective, we predominantly focus on the impact of SARS-CoV-2" exact="infection" post="on ACE2 and dysregulation of the protective effect of"/>
 <result pre="of the protective effect of the ACE2/MAS pathway in alveolar" exact="epithelial" post="cells and how this may amplify systemic deleterious effect"/>
 <result pre="pathway in alveolar epithelial cells and how this may amplify" exact="systemic" post="deleterious effect of renin-angiotensin aldosterone system (RAS) in the"/>
 <result pre="or by developing targeted drugs to inhibit proteases required for" exact="viral" post="entry. COVID-19 lung alveolar angiotensin coagulopathy fig-count: table-count: equation-count:"/>
 <result pre="inhibit proteases required for viral entry. COVID-19 lung alveolar angiotensin" exact="coagulopathy" post="fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Severe acute"/>
 <result pre="alveolar angiotensin coagulopathy fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction" exact="Severe" post="acute respiratory syndrome virus 2 (SARS-CoV-2) causes a respiratory"/>
 <result pre="angiotensin coagulopathy fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Severe" exact="acute" post="respiratory syndrome virus 2 (SARS-CoV-2) causes a respiratory disease"/>
 <result pre="coagulopathy fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Severe acute" exact="respiratory" post="syndrome virus 2 (SARS-CoV-2) causes a respiratory disease that"/>
 <result pre="fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Severe acute respiratory" exact="syndrome" post="virus 2 (SARS-CoV-2) causes a respiratory disease that led"/>
 <result pre="Introduction Severe acute respiratory syndrome virus 2 (SARS-CoV-2) causes a" exact="respiratory" post="disease that led to the fatal Coronavirus disease 2019"/>
 <result pre="Severe acute respiratory syndrome virus 2 (SARS-CoV-2) causes a respiratory" exact="disease" post="that led to the fatal Coronavirus disease 2019 (COVID-19)"/>
 <result pre="causes a respiratory disease that led to the fatal Coronavirus" exact="disease" post="2019 (COVID-19) pandemic. In late 2019, the SARS-CoV-2 outbreak"/>
 <result pre="non-segmented positive-sense RNA viruses. They generally cause mild enteric and" exact="respiratory" post="diseases in animals and humans (Glass et al., 2004)."/>
 <result pre="as hCoV-229E, OC43, NL63, and HKU1 usually cause only mild" exact="respiratory" post="diseases (Fouchier et al., 2004). SARS-CoV-2 causes acute, highly"/>
 <result pre="diseases (Fouchier et al., 2004). SARS-CoV-2 causes acute, highly lethal" exact="pneumonia" post="with clinical symptoms similar to those reported for SARS-CoV"/>
 <result pre="2004). In contrast to SARS-CoV, SARS-CoV-2-infected patients rarely show prominent" exact="upper" post="respiratory tract signs and symptoms. On presentation, most infected"/>
 <result pre="In contrast to SARS-CoV, SARS-CoV-2-infected patients rarely show prominent upper" exact="respiratory" post="tract signs and symptoms. On presentation, most infected individuals"/>
 <result pre="exhibit dry cough (83â€&quot;99%), and dyspnea (59.4â€&quot;82%) with findings of" exact="bilateral" post="ground-glass opacities on radiographic images (Guo et al., 2020;"/>
 <result pre="al., 2020). In most severe cases the characteristic symptom is" exact="respiratory" post="distress (~55%) Grasselli et al. The reported mortality varies"/>
 <result pre="literature, most severe SARS-CoV-2 cases progressed within 14â€&quot;21 days after" exact="disease" post="onset. Various laboratory abnormalities have been observed even preceding"/>
 <result pre="Various laboratory abnormalities have been observed even preceding the significant" exact="respiratory" post="dysfunction (Lu et al., 2020). Mortality related to SARS-CoV-2"/>
 <result pre="predominantly reported in elderly or subjects with preexisting conditions, predominantly" exact="cardiovascular" post="diseases such as hypertension and congestive heart failure (Zhou"/>
 <result pre="or subjects with preexisting conditions, predominantly cardiovascular diseases such as" exact="hypertension" post="and congestive heart failure (Zhou et al., 2020). Interestingly,"/>
 <result pre="with preexisting conditions, predominantly cardiovascular diseases such as hypertension and" exact="congestive heart failure" post="(Zhou et al., 2020). Interestingly, these risk factors are"/>
 <result pre="preexisting conditions, predominantly cardiovascular diseases such as hypertension and congestive" exact="heart" post="failure (Zhou et al., 2020). Interestingly, these risk factors"/>
 <result pre="(diabetes, hypertension, obesity) associated with MERS-CoV related mortality, although MERS-CoV" exact="respiratory" post="disease occurred in younger individuals (Assiri et al., 2013;"/>
 <result pre="hypertension, obesity) associated with MERS-CoV related mortality, although MERS-CoV respiratory" exact="disease" post="occurred in younger individuals (Assiri et al., 2013; World"/>
 <result pre="50 years. Given the fact of a higher prevalence of" exact="metabolic diseases," post="including obesity, hypertension, cardiovascular diseases and diabetes in the"/>
 <result pre="of a higher prevalence of metabolic diseases, including obesity, hypertension," exact="cardiovascular" post="diseases and diabetes in the US population (Moore et"/>
 <result pre="prevalence of metabolic diseases, including obesity, hypertension, cardiovascular diseases and" exact="diabetes" post="in the US population (Moore et al., 2017), this"/>
 <result pre="diabetes in the US population (Moore et al., 2017), this" exact="infection" post="may cause higher mortality. The virus gains entrance into"/>
 <result pre="receptor. How the known epidemiological and clinical manifestation of SARS-CoV-2" exact="infection" post="may be explained by perturbations of physiological functions of"/>
 <result pre="single-stranded positive-sense RNA virus, containing ~26â€&quot;32 kilobase (kb) genome. The" exact="viral" post="envelope consists of a lipid bilayer, where the viral"/>
 <result pre="The viral envelope consists of a lipid bilayer, where the" exact="viral" post="membrane (M), envelope (E), and spike (S) structural proteins"/>
 <result pre="2002; Li et al., 2003). Similar to other CoV, during" exact="viral" post="entry into the host cell, the spike proteins (S)"/>
 <result pre="been identified. Proteolytic cleavage is followed by fusion of the" exact="viral" post="and cellular membranes. Furthermore, it has been shown that"/>
 <result pre="(ectodomain and endodomain) by ADAM17 and TMPRSS2 facilitate effective cellular" exact="viral" post="entry. It appears that this process leads to shedding"/>
 <result pre="that may contribute to the loss of ACE2 function and" exact="systemic" post="release of S1/ACE2 complex. Generally fusion with the host"/>
 <result pre="antiparallel six-helix bundle facilitating the fusion and release of the" exact="viral" post="genome into the cytoplasm. The viral replication genome of"/>
 <result pre="and release of the viral genome into the cytoplasm. The" exact="viral" post="replication genome of CoVs contains a variable number (World"/>
 <result pre="Baud et al.) of open reading frames (ORFs). Two-thirds of" exact="viral" post="RNA, mainly located in the first ORF (ORF1a/b) translates"/>
 <result pre="and Perlman, 2015). After replication and subgenomic RNA synthesis, the" exact="viral" post="structural proteins, S, E, and M are translated and"/>
 <result pre="by movement along the secretory pathway into the endoplasmic reticulum-Golgi" exact="intermediate" post="(Krijnse-Locker et al., 1994; Fehr and Perlman, 2015). The"/>
 <result pre="two proteins function together to produce coronavirus envelopes. Mechanism of" exact="Disease" post="Effect of SARS-CoV-2 Infection on Renin/Angiotensin System Because of"/>
 <result pre="to produce coronavirus envelopes. Mechanism of Disease Effect of SARS-CoV-2" exact="Infection" post="on Renin/Angiotensin System Because of the central role of"/>
 <result pre="Because of the central role of ACE2 receptor as the" exact="viral" post="entry point, the understanding of the functional role of"/>
 <result pre="cellular signaling may explain the observed clinical picture of severe" exact="respiratory" post="distress, myocardial injury, renal failure, and increased mortality due"/>
 <result pre="the observed clinical picture of severe respiratory distress, myocardial injury," exact="renal failure," post="and increased mortality due to SARS-CoV-2 infection among the"/>
 <result pre="myocardial injury, renal failure, and increased mortality due to SARS-CoV-2" exact="infection" post="among the aging population and subjects with cardiovascular and"/>
 <result pre="to SARS-CoV-2 infection among the aging population and subjects with" exact="cardiovascular" post="and metabolic diseases (Zhou et al., 2020; Zhu et"/>
 <result pre="infection among the aging population and subjects with cardiovascular and" exact="metabolic diseases" post="(Zhou et al., 2020; Zhu et al., 2020). ACE"/>
 <result pre="exons (Turner et al., 2002). The ACE2 gene encodes a" exact="type I" post="membrane-bound glycoprotein composed of 805 amino acids (Marian, 2013)."/>
 <result pre="in almost all tissues, while ACE2 is expressed on alveolar" exact="epithelial" post="cells and capillary endothelial cells. ACE2 is highly expressed"/>
 <result pre="as lungs and kidneys but also in the gut and" exact="brain" post="(Hamming et al., 2004; Tikellis and Thomas, 2012; Roca-Ho"/>
 <result pre="Genetic polymorphisms of ACE and ACE2 are associated with hypertension," exact="cardiovascular disease," post="stroke, and diabetes (Crackower et al., 2002; Ramachandran et"/>
 <result pre="and ACE2 are associated with hypertension, cardiovascular disease, stroke, and" exact="diabetes" post="(Crackower et al., 2002; Ramachandran et al., 2008; Jang"/>
 <result pre="is catalyzed by ACE. ACE is expressed primarily in the" exact="vascular" post="endothelium of the lungs and kidneys (Wakahara et al.,"/>
 <result pre="2007), but also on the epithelium of the lungs and" exact="upper" post="respiratory system. After Ang I is converted to Ang"/>
 <result pre="but also on the epithelium of the lungs and upper" exact="respiratory" post="system. After Ang I is converted to Ang II,"/>
 <result pre="is converted to Ang II, it binds to angiotensin II" exact="type I" post="(AT) and type II receptors in the kidney, adrenal"/>
 <result pre="II, it binds to angiotensin II type I (AT) and" exact="type II" post="receptors in the kidney, adrenal cortex, arterioles, and the"/>
 <result pre="II receptors in the kidney, adrenal cortex, arterioles, and the" exact="brain" post="(Figure 1A). Ang II acts on the adrenal cortex"/>
 <result pre="of aldosterone (Xue et al., 2011), leading to sodium and" exact="water retention." post="While the effects of Ang II are rapid, the"/>
 <result pre="physiological net effects of RAS activation is an increase in" exact="total" post="body sodium, total body water, and increased vascular tone."/>
 <result pre="of RAS activation is an increase in total body sodium," exact="total" post="body water, and increased vascular tone. Furthermore, the binding"/>
 <result pre="increase in total body sodium, total body water, and increased" exact="vascular" post="tone. Furthermore, the binding of Ang II to AT"/>
 <result pre="and Holstein-Rathlou, 1999), endothelial injury (Watanabe et al., 2005), endovascular" exact="thrombosis" post="(Tay and Lip, 2008) and increase blood volume. Increased"/>
 <result pre="endovascular thrombosis (Tay and Lip, 2008) and increase blood volume." exact="Increased" post="Ang II is associated with hypertension and accelerated thrombosis"/>
 <result pre="and increase blood volume. Increased Ang II is associated with" exact="hypertension" post="and accelerated thrombosis in arterioles by activating the coagulation"/>
 <result pre="volume. Increased Ang II is associated with hypertension and accelerated" exact="thrombosis" post="in arterioles by activating the coagulation cascade (both thrombin"/>
 <result pre="and inhibits the production of nitric oxide and hence promotes" exact="vascular" post="injury (Kato et al., 1996; Nabah et al., 2004)."/>
 <result pre="II is a potent vasoconstrictor and detrimental for endothelial and" exact="epithelial" post="function through activating AT1 and AT2 receptors. The counterbalance"/>
 <result pre="death. (B) SARS-CoV-2 binds to ACE2 to gain entry to" exact="epithelial" post="cells of the lungs. Cleavage of spike proteins by"/>
 <result pre="or ADAM17 on ectodomain and TMPRSS2 of endodomain sites facilitate" exact="viral" post="entry into the cells. This process leads to shedding"/>
 <result pre="its protective functions including vasodilatation, cell protection both at the" exact="epithelial" post="and endothelial sites. Loss of ACE2 function leads to"/>
 <result pre="Upregulation of Ang II leads to vasoconstriction, thrombophilia, microthrombosis, alveolar" exact="epithelial" post="injury and respiratory failure. Therefore, inhibiting the proteolytic function"/>
 <result pre="II leads to vasoconstriction, thrombophilia, microthrombosis, alveolar epithelial injury and" exact="respiratory" post="failure. Therefore, inhibiting the proteolytic function of trypsin/cathepsin and"/>
 <result pre="2011; Uehara et al., 2013). Most of these proteases are" exact="localized" post="in specific tissues (lungs, myocardium, arterioles, kidney, or brain)"/>
 <result pre="using ACE inhibitors, only decreased Ang II levels for a" exact="short" post="period of time, and Ang II levels return to"/>
 <result pre="that upregulation of ACE2 may provide more available receptors for" exact="viral" post="entry and hence a higher viral load associated with"/>
 <result pre="more available receptors for viral entry and hence a higher" exact="viral" post="load associated with poor prognosis (Chu et al., 2004)."/>
 <result pre="ACE2 receptors exhibit cardiac systolic dysfunction, increased blood pressure, myocardial" exact="interstitial fibrosis," post="endothelial dysfunction, and exhibit increased susceptibility to intravascular thrombosis,"/>
 <result pre="blood pressure, myocardial interstitial fibrosis, endothelial dysfunction, and exhibit increased" exact="susceptibility to" post="intravascular thrombosis, chronic kidney disease, metabolic abnormalities, and various"/>
 <result pre="fibrosis, endothelial dysfunction, and exhibit increased susceptibility to intravascular thrombosis," exact="chronic" post="kidney disease, metabolic abnormalities, and various other biological abnormalities"/>
 <result pre="endothelial dysfunction, and exhibit increased susceptibility to intravascular thrombosis, chronic" exact="kidney disease," post="metabolic abnormalities, and various other biological abnormalities that regulate"/>
 <result pre="metabolic abnormalities, and various other biological abnormalities that regulate the" exact="cardiovascular" post="system (Yamamoto et al., 2006; Tikellis and Thomas, 2012)."/>
 <result pre="cells and organisms, such as cell death, fibrosis, angiogenesis, and" exact="thrombosis" post="formation (Fraga-Silva et al., 2010; Tikellis and Thomas, 2012)."/>
 <result pre="Thomas, 2012). Recent autopsy results on SARS-CoV-2 infected humans showed" exact="diffuse" post="alveolar damage with massive capillary congestion accompanied by microthrombi"/>
 <result pre="alveolar damage with massive capillary congestion accompanied by microthrombi in" exact="vascular" post="beds but a paucity of inflammatory infiltrates (Menter et"/>
 <result pre="However, pathological examination on autopsies have not investigated if SARS-CoV-2" exact="infection" post="leads to total destruction of ACE2 receptors on the"/>
 <result pre="on autopsies have not investigated if SARS-CoV-2 infection leads to" exact="total" post="destruction of ACE2 receptors on the alveolar epithelial and"/>
 <result pre="leads to total destruction of ACE2 receptors on the alveolar" exact="epithelial" post="and endothelial cells. Interestingly, in an animal model of"/>
 <result pre="et al. found a marked decreased ACE2 expression in the" exact="heart" post="of infected mice (Oudit et al., 2009). The key"/>
 <result pre="as vasodilation, inhibition of cell growth, and protection from alveolar" exact="epithelial" post="cell injury. In addition, it has antifibrotic, anti-thrombotic, and"/>
 <result pre="that the ACE2-Ang-(1-7)-MAS axis has a protective effect on the" exact="brain" post="and prevents ischemic stroke (Jiang et al., 2013). Direct"/>
 <result pre="has a protective effect on the brain and prevents ischemic" exact="stroke" post="(Jiang et al., 2013). Direct Protective Actions of ACE2"/>
 <result pre="et al., 2013). Direct Protective Actions of ACE2 on Lung" exact="Alveolar" post="Epithelial Cells In addition to its protective role in"/>
 <result pre="Epithelial Cells In addition to its protective role in the" exact="cardiovascular" post="system, ACE2 has a direct protective role in alveolar"/>
 <result pre="cardiovascular system, ACE2 has a direct protective role in alveolar" exact="epithelial" post="cells. In the lungs ACE2 has numerous physiological functions,"/>
 <result pre="degrading Ang II, which is vasoconstrictive and proapoptotic for lung" exact="epithelial" post="cells (Wang et al., 1999) and profibrotic (Li et"/>
 <result pre="administered to experimental animals, protect against lung cell death, inhibit" exact="acute" post="lung injury and prevent lung fibrosis after chronic injury"/>
 <result pre="against lung cell death, inhibit acute lung injury and prevent" exact="lung fibrosis" post="after chronic injury to the lungs (Li et al.,"/>
 <result pre="death, inhibit acute lung injury and prevent lung fibrosis after" exact="chronic" post="injury to the lungs (Li et al., 2008; Rey-Parra"/>
 <result pre="application of a specific competitive inhibitor of ACE2, DX600, to" exact="primary" post="cultures of isolated ACEs increases the level of Ang"/>
 <result pre="et al., 2020). Thus, functional ACE2 normally expressed by alveolar" exact="epithelial" post="cells can be viewed as a critical survival factor"/>
 <result pre="Forster, 1997). If Ang1-7 is applied to cultures of lung" exact="epithelial" post="cells, it can prevent lung cell death in response"/>
 <result pre="been shown to protect the lungs in preclinical models of" exact="acute" post="lung injury (Simoes e Silva et al., 2013; Gopallawa"/>
 <result pre="al., 2013; Gopallawa and Uhal, 2014). Therapeutic Strategies for SARS-CoV-2" exact="Infection" post="Currently, there are no targeted drugs specifically against SARS-CoV-2."/>
 <result pre="treatments. Among those, lopinavir, originally used for treatment of human" exact="immunodeficiency" post="virus, was identified to have potential antiviral activity against"/>
 <result pre="activity against SARS-CoV-2. Unfortunately, a randomized-controlled, open-label trial involving hospitalized" exact="adult" post="patients with confirmed SARS-CoV-2 infection showed no benefit of"/>
 <result pre="randomized-controlled, open-label trial involving hospitalized adult patients with confirmed SARS-CoV-2" exact="infection" post="showed no benefit of lopanavir (Cao et al., 2020)."/>
 <result pre="that at micromolar concentration of remdesivir and chloroquine potentially blocked" exact="virus infection" post="(Wang M. et al., 2020). Current clinical trials are"/>
 <result pre="at micromolar concentration of remdesivir and chloroquine potentially blocked virus" exact="infection" post="(Wang M. et al., 2020). Current clinical trials are"/>
 <result pre="drugs that are also used as antiinflammatory drugs in various" exact="autoimmune diseases," post="including rheumatoid arthritis, Lupus erythematosus, and respiratory diseases such"/>
 <result pre="also used as antiinflammatory drugs in various autoimmune diseases, including" exact="rheumatoid arthritis," post="Lupus erythematosus, and respiratory diseases such as sarcoidosis (Martin"/>
 <result pre="as antiinflammatory drugs in various autoimmune diseases, including rheumatoid arthritis," exact="Lupus" post="erythematosus, and respiratory diseases such as sarcoidosis (Martin et"/>
 <result pre="in various autoimmune diseases, including rheumatoid arthritis, Lupus erythematosus, and" exact="respiratory" post="diseases such as sarcoidosis (Martin et al., 2009; Talreja"/>
 <result pre="including rheumatoid arthritis, Lupus erythematosus, and respiratory diseases such as" exact="sarcoidosis" post="(Martin et al., 2009; Talreja et al., 2019). Despite"/>
 <result pre="significant efficacy of antimalarial drugs in the treatment of SARS-CoV-2" exact="infection" post="(Magagnoli et al., 2020). Corticosteroids are the most conventional"/>
 <result pre="of scientific data. Furthermore, because of the high incidence of" exact="arterial hypertension," post="diabetes, and congestive heart failure in subjects with COVID-19,"/>
 <result pre="because of the high incidence of arterial hypertension, diabetes, and" exact="congestive heart failure" post="in subjects with COVID-19, corticosteroids should be used with"/>
 <result pre="of the high incidence of arterial hypertension, diabetes, and congestive" exact="heart" post="failure in subjects with COVID-19, corticosteroids should be used"/>
 <result pre="related risk factors for hospitalization and mortality among patients with" exact="metabolic diseases," post="including obesity, arterial hypertension, cardiovascular diseases, and diabetes that"/>
 <result pre="hospitalization and mortality among patients with metabolic diseases, including obesity," exact="arterial hypertension," post="cardiovascular diseases, and diabetes that may reflect overall activation"/>
 <result pre="mortality among patients with metabolic diseases, including obesity, arterial hypertension," exact="cardiovascular" post="diseases, and diabetes that may reflect overall activation of"/>
 <result pre="with metabolic diseases, including obesity, arterial hypertension, cardiovascular diseases, and" exact="diabetes" post="that may reflect overall activation of the RAS system,"/>
 <result pre="most patients present with relatively preserved hemodynamics and lack of" exact="lactic acidosis." post="But they have respiratory distress, appear to be in"/>
 <result pre="preserved hemodynamics and lack of lactic acidosis. But they have" exact="respiratory" post="distress, appear to be in a hypercoagulable state (Liu"/>
 <result pre="(Liu et al., 2020; Menter et al., 2020), exhibit progressive" exact="renal failure" post="(Cheng et al., 2020), have stroke like features and"/>
 <result pre="2020), exhibit progressive renal failure (Cheng et al., 2020), have" exact="stroke" post="like features and myocardial injury (Zhou et al., 2020)."/>
 <result pre="2020). Clinical observational studies indicate that in most cases the" exact="respiratory" post="distress occurs many days (in general about 14 days)"/>
 <result pre="this may not be a direct effect of the initial" exact="viral infection" post="but rather the hosts reaction to the loss of"/>
 <result pre="may not be a direct effect of the initial viral" exact="infection" post="but rather the hosts reaction to the loss of"/>
 <result pre="the detrimental effects of increased Ang II contributing to lung" exact="epithelial" post="and endovascular injury. Therefore, induction of the downstream pathway"/>
 <result pre="axis may prove a useful strategy in preventing lung and" exact="cardiovascular" post="damage associated with SARS-CoV-2 infections. Because decreased ACE2/MAS activity"/>
 <result pre="the Ang II/AT1R activity and its hazardous consequence on increased" exact="pulmonary" post="vascular endothelial/epithelial injury and lung pathology. Inhibiting the activity"/>
 <result pre="Ang II/AT1R activity and its hazardous consequence on increased pulmonary" exact="vascular" post="endothelial/epithelial injury and lung pathology. Inhibiting the activity of"/>
 <result pre="pathology. Inhibiting the activity of proteases necessary for cleavage of" exact="viral" post="spike proteins: for instance inhibition of enzymatic activity of"/>
 <result pre="serve as other novel therapeutic targets. This could potentially block" exact="viral" post="interaction with the receptor and its entry into the"/>
 <result pre="Ang II is feasible and might be effective for the" exact="symptomatic" post="treatment of these patients. Concluding Remarks Based on the"/>
 <result pre="effect of SARS-CoV-2 virus binding to ACE2 and how the" exact="viral" post="binding on this receptor may modulate the ACE2 enzymatic"/>
 <result pre="its enzymatic activity, and on its protective actions toward lung" exact="epithelial" post="cells and lung injury? (2) What effect(s) does SARS-CoV-2"/>
 <result pre="epithelial cells and lung injury? (2) What effect(s) does SARS-CoV-2" exact="infection" post="of lung epithelial cells/endothelial cells have on ACE2 expression"/>
 <result pre="lung injury? (2) What effect(s) does SARS-CoV-2 infection of lung" exact="epithelial" post="cells/endothelial cells have on ACE2 expression in the lungs"/>
 <result pre="on the binding of SARS-CoV-2 to the ACE2 receptor and/or" exact="infection" post="of lung epithelial cells? Regardless, these are questions of"/>
 <result pre="of SARS-CoV-2 to the ACE2 receptor and/or infection of lung" exact="epithelial" post="cells? Regardless, these are questions of fundamental importance to"/>
 <result pre="The authors declare that the research was conducted in the" exact="absence of" post="any commercial or financial relationships that could be construed"/>
 <result pre="demographic, and clinical characteristics of 47 cases of Middle East" exact="respiratory" post="syndrome coronavirus disease from Saudi Arabia: a descriptive study."/>
 <result pre="and clinical characteristics of 47 cases of Middle East respiratory" exact="syndrome" post="coronavirus disease from Saudi Arabia: a descriptive study. Lancet"/>
 <result pre="characteristics of 47 cases of Middle East respiratory syndrome coronavirus" exact="disease" post="from Saudi Arabia: a descriptive study. Lancet Infect Dis.13,"/>
 <result pre="O. (2011). Alternative pathways for angiotensin II generation in the" exact="cardiovascular" post="system. Braz. J. Med. Biol. Res.44, 914â€&quot;919. 10.1590/S0100-879X201100750009321956534 BelouzardS.ChuV."/>
 <result pre="-CostaN.Xavier Gomis-RÃ¼thF. (2014). Architecture and function of metallopeptidase catalytic domains." exact="Protein" post="Sci.23, 123â€&quot;144. 10.1002/pro.240024596965 ChengY.LuoR.WangK.ZhangM.WangZ.DongL.et al.. (2020). Kidney disease is"/>
 <result pre="metallopeptidase catalytic domains. Protein Sci.23, 123â€&quot;144. 10.1002/pro.240024596965 ChengY.LuoR.WangK.ZhangM.WangZ.DongL.et al.. (2020)." exact="Kidney" post="disease is associated with in-hospital death of patients with"/>
 <result pre="catalytic domains. Protein Sci.23, 123â€&quot;144. 10.1002/pro.240024596965 ChengY.LuoR.WangK.ZhangM.WangZ.DongL.et al.. (2020). Kidney" exact="disease" post="is associated with in-hospital death of patients with COVID-19."/>
 <result pre="disease is associated with in-hospital death of patients with COVID-19." exact="Kidney" post="Int. 97, 829â€&quot;838. 10.1016/j.kint.2020.03.00532247631 ChuC.-M.PoonL. L.ChengV. C.ChanK.-S.HungI. F.WongM. M.et"/>
 <result pre="829â€&quot;838. 10.1016/j.kint.2020.03.00532247631 ChuC.-M.PoonL. L.ChengV. C.ChanK.-S.HungI. F.WongM. M.et al.. (2004). Initial" exact="viral" post="load and the outcomes of SARS. CMAJ171, 1349â€&quot;1352. 10.1503/cmaj.104039815557587"/>
 <result pre="al.. (2002). Angiotensin-converting enzyme 2 is an essential regulator of" exact="heart" post="function. Nature417, 822â€&quot;828. 10.1038/nature0078612075344 de KloetA. D.KrauseE. G.WoodsS. C."/>
 <result pre="D.KrauseE. G.WoodsS. C. (2010). The renin angiotensin system and the" exact="metabolic syndrome." post="Physiol. Behav.100, 525â€&quot;534. 10.1016/j.physbeh.2010.03.01820381510 DiazJ. H. (2020). Hypothesis: angiotensin-converting"/>
 <result pre="C.SimonJ. H.et al.. (2004). A previously undescribed coronavirus associated with" exact="respiratory" post="disease in humans. Proc. Natl. Acad. Sci. U.S.A.101, 6212â€&quot;6216."/>
 <result pre="H.et al.. (2004). A previously undescribed coronavirus associated with respiratory" exact="disease" post="in humans. Proc. Natl. Acad. Sci. U.S.A.101, 6212â€&quot;6216. 10.1073/pnas.040076210115073334"/>
 <result pre="(1999). Induction of interleukin-6 expression by angiotensin II in rat" exact="vascular" post="smooth muscle cells. Hypertension34, 118â€&quot;125. 10.1161/01.HYP.34.1.11810406834 GarridoA. M.GriendlingK. K."/>
 <result pre="of interleukin-6 expression by angiotensin II in rat vascular smooth" exact="muscle" post="cells. Hypertension34, 118â€&quot;125. 10.1161/01.HYP.34.1.11810406834 GarridoA. M.GriendlingK. K. (2009). NADPH"/>
 <result pre="GlassW. G.SubbaraoK.MurphyB.MurphyP. M. (2004). Mechanisms of host defense following severe" exact="acute" post="respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J. Immunol.173,"/>
 <result pre="G.SubbaraoK.MurphyB.MurphyP. M. (2004). Mechanisms of host defense following severe acute" exact="respiratory" post="syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J. Immunol.173, 4030â€&quot;4039."/>
 <result pre="Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV)" exact="pulmonary" post="infection of mice. J. Immunol.173, 4030â€&quot;4039. 10.4049/jimmunol.173.6.403015356152 GopallawaI.UhalB. D."/>
 <result pre="of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary" exact="infection" post="of mice. J. Immunol.173, 4030â€&quot;4039. 10.4049/jimmunol.173.6.403015356152 GopallawaI.UhalB. D. (2014)."/>
 <result pre="Curr. Top. Pharmacol.18:71. 26146467 GopallawaI.UhalB. D. (2016). Translational research in" exact="acute" post="lung injury and pulmonary fibrosis: angiotensin-(1-7)/mas inhibits apoptosis in"/>
 <result pre="GopallawaI.UhalB. D. (2016). Translational research in acute lung injury and" exact="pulmonary" post="fibrosis: angiotensin-(1-7)/mas inhibits apoptosis in alveolar epithelial cells through"/>
 <result pre="lung injury and pulmonary fibrosis: angiotensin-(1-7)/mas inhibits apoptosis in alveolar" exact="epithelial" post="cells through upregulation of MAP kinase phosphatase-2. Am. J."/>
 <result pre="al.. (2020). The origin, transmission and clinical therapies on coronavirus" exact="disease" post="2019 (COVID-19) outbreakâ€&quot;an update on the status. Military Med."/>
 <result pre="HanY.RungeM. S.BrasierA. R. (1999). Angiotensin II induces interleukin-6 transcription in" exact="vascular" post="smooth muscle cells through pleiotropic activation of nuclear factor-ÎºB"/>
 <result pre="R. (1999). Angiotensin II induces interleukin-6 transcription in vascular smooth" exact="muscle" post="cells through pleiotropic activation of nuclear factor-ÎºB transcription factors."/>
 <result pre="only proteolysis by TMPRSS2 augments entry driven by the severe" exact="acute" post="respiratory syndrome coronavirus spike protein. J. Virol.88, 1293â€&quot;1307. 10.1128/JVI.02202-1324227843"/>
 <result pre="proteolysis by TMPRSS2 augments entry driven by the severe acute" exact="respiratory" post="syndrome coronavirus spike protein. J. Virol.88, 1293â€&quot;1307. 10.1128/JVI.02202-1324227843 HoffmannM.Kleine-WeberH.SchroederS.KrÃ¼gerN.HerrlerT.ErichsenS.et"/>
 <result pre="by TMPRSS2 augments entry driven by the severe acute respiratory" exact="syndrome" post="coronavirus spike protein. J. Virol.88, 1293â€&quot;1307. 10.1128/JVI.02202-1324227843 HoffmannM.Kleine-WeberH.SchroederS.KrÃ¼gerN.HerrlerT.ErichsenS.et al.."/>
 <result pre="A.BrosnihanK. B.FerrarioC. M. (2004). Upregulation of angiotensin-converting enzyme 2 after" exact="myocardial infarction" post="by blockade of angiotensin II receptors. Hypertension43, 970â€&quot;976. 10.1161/01.HYP.0000124667.34652.1a15007027"/>
 <result pre="17229979 Krijnse-LockerJ.EricssonM.RottierP.GriffithsG. (1994). Characterization of the budding compartment of mouse" exact="hepatitis" post="virus: evidence that transport from the RER to the"/>
 <result pre="Biol.124, 55â€&quot;70. 10.1083/jcb.124.1.558294506 LambertD. W.YarskiM.WarnerF. J.ThornhillP.ParkinE. T.SmithA. I.et al.. (2005)." exact="Tumor" post="necrosis factor-Î± convertase (ADAM17) mediates regulated ectodomain shedding of"/>
 <result pre="factor-Î± convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute" exact="respiratory" post="syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J. Biol. Chem.280,"/>
 <result pre="converting enzyme-2 is protective but downregulated in human and experimental" exact="lung fibrosis." post="Am. J. Physiol. Lung Cell. Mol. Physiol.295, L178â€&quot;L185. 10.1152/ajplung.00009.200818441099"/>
 <result pre="medRxiv. 10.1101/2020.02.27.20027557 LorenzJ. N. (2010). Chymase: The Other ACE?Bethesda, MD:" exact="American" post="Physiological Society. LuH.AiJ.ShenY.LiY.LiT.ZhouX.et al. (2020). A descriptive study of"/>
 <result pre="MartinR. E.MarchettiR. V.CowanA. I.HowittS. M.BrÃ¶erS.KirkK. (2009). Chloroquine transport via the" exact="malaria" post="parasite's chloroquine resistance transporter. Science325, 1680â€&quot;1682. 10.1126/science.117566719779197 MenterT.HaslbauerJ. D.NienholdR.SavicS.HopferH.DeigendeschN.et"/>
 <result pre="MenterT.HaslbauerJ. D.NienholdR.SavicS.HopferH.DeigendeschN.et al.. (2020). Post-mortem examination of COVID19 patients reveals" exact="diffuse" post="alveolar damage with severe capillary congestion and variegated findings"/>
 <result pre="congestion and variegated findings of lungs and other organs suggesting" exact="vascular" post="dysfunction. Histopathology. 10.1111/his.14134. [Epub ahead of print]. 32364264 MentoP."/>
 <result pre="converting enzyme inhibition. Hypertension9:III42. 10.1161/01.HYP.9.6_Pt_2.III423036705 MooreJ. X.ChaudharyN.AkinyemijuT. (2017). Peer reviewed:" exact="metabolic syndrome" post="prevalence by race/ethnicity and sex in the United States,"/>
 <result pre="enzyme inhibition. Hypertension9:III42. 10.1161/01.HYP.9.6_Pt_2.III423036705 MooreJ. X.ChaudharyN.AkinyemijuT. (2017). Peer reviewed: metabolic" exact="syndrome" post="prevalence by race/ethnicity and sex in the United States,"/>
 <result pre="United States, National Health and Nutrition Examination Survey, 1988â€&quot;2012. Prev." exact="Chronic" post="Dis.14:E24. 10.5888/pcd14.16028728301314 MulanguS.DoddL. E.DaveyR. T.JrTshiani MbayaO.ProschanM.MukadiD.et al.. (2019). A"/>
 <result pre="MbayaO.ProschanM.MukadiD.et al.. (2019). A randomized, controlled trial of Ebola virus" exact="disease" post="therapeutics. N. Engl. J. Med.381, 2293â€&quot;2303. 10.1056/NEJMoa191099331774950 NabahY. N."/>
 <result pre="The unfolded protein response controls ER stress-induced apoptosis of lung" exact="epithelial" post="cells through angiotensin generation. Am. J. Physiol. Lung Cell."/>
 <result pre="(2015). Hyperoxia downregulates angiotensin-converting enzyme-2 in human fetal lung fibroblasts." exact="Pediatric" post="Res.77, 656â€&quot;662. 10.1038/pr.2015.2725665060 OuditG.KassiriZ.JiangC.LiuP.PoutanenS.PenningerJ.et al.. (2009). SARS-coronavirus modulation of"/>
 <result pre="(2008). Association of insertion/deletion polymorphism of angiotensin-converting enzyme gene with" exact="essential hypertension" post="and type 2 diabetes mellitus in Malaysian subjects. J."/>
 <result pre="Association of insertion/deletion polymorphism of angiotensin-converting enzyme gene with essential" exact="hypertension" post="and type 2 diabetes mellitus in Malaysian subjects. J."/>
 <result pre="insertion/deletion polymorphism of angiotensin-converting enzyme gene with essential hypertension and" exact="type 2" post="diabetes mellitus in Malaysian subjects. J. Renin Angiotensin Aldosterone"/>
 <result pre="of angiotensin-converting enzyme gene with essential hypertension and type 2" exact="diabetes mellitus" post="in Malaysian subjects. J. Renin Angiotensin Aldosterone Syst.9, 208â€&quot;214."/>
 <result pre="the synthesis of proinflammatory cytokines and chemokines in the kidney." exact="Kidney" post="Int.62, S12â€&quot;S22. 10.1046/j.1523-1755.62.s82.4.x12410849 SantosR. A.e SilvaA. C. S.MaricC.SilvaD. M.MachadoR."/>
 <result pre="SchindlerC.BramlageP.KirchW.FerrarioC. M. (2007). Role of the vasodilator peptide angiotensin-(1-7) in" exact="cardiovascular" post="drug therapy. Vasc. Health Risk Manage.3:125. 17583183 SenchenkovaE. Y.RussellJ.Almeida-PaulaL."/>
 <result pre="Pharm. Des.19, 3054â€&quot;3059. 10.2174/138161281131917001223176219 UhalB. D.LiX.XueA.GaoX.Abdul-HafezA. (2011). Regulation of alveolar" exact="epithelial" post="cell survival by the ACE-2/angiotensin 1-7/Mas axis. Am. J."/>
 <result pre="A. (1996). Potentiation of angiotensin II action by corticosteroids in" exact="vascular" post="tissue. Cardiovasc. Res.32, 266â€&quot;273. 10.1016/0008-6363(96)00053-38796113 WakaharaS.KonoshitaT.MizunoS.MotomuraM.AoyamaC.MakinoY.et al.. (2007). Synergistic"/>
 <result pre="and ACE2 in human renal tissue and confounding effects of" exact="hypertension" post="on the ACE to ACE2 ratio. Endocrinology148, 2453â€&quot;2457. 10.1210/en.2006-128717303661"/>
 <result pre="(2019-nCoV) in vitro. Cell Res.30, 269â€&quot;271. 10.1038/s41422-020-0282-032020029 WangQ.ZhangY.WuL.NiuS.SongC.ZhangZ.et al.. (2020)." exact="Structural" post="and functional basis of SARS-CoV-2 entry by using human"/>
 <result pre="(1999). Angiotensin II induces apoptosis in human and rat alveolar" exact="epithelial" post="cells. Am. J. Physiol. Lung Cell. Mol. Physiol.276, L885â€&quot;L889."/>
 <result pre="(2013). Revised Interim Case Definition for Reporting to WHO-Middle East" exact="Respiratory" post="Syndrome Coronavirus (MERS-CoV) (Geneva). XueB.BeltzT. G.YuY.GuoF.Gomez-SanchezC. E.HayM.et al.. (2011)."/>
 <result pre="Revised Interim Case Definition for Reporting to WHO-Middle East Respiratory" exact="Syndrome" post="Coronavirus (MERS-CoV) (Geneva). XueB.BeltzT. G.YuY.GuoF.Gomez-SanchezC. E.HayM.et al.. (2011). Central"/>
 <result pre="Respiratory Syndrome Coronavirus (MERS-CoV) (Geneva). XueB.BeltzT. G.YuY.GuoF.Gomez-SanchezC. E.HayM.et al.. (2011)." exact="Central" post="interactions of aldosterone and angiotensin II in aldosterone-and angiotensin"/>
 <result pre="angiotensin II in aldosterone-and angiotensin II-induced hypertension. Am. J. Physiol." exact="Heart" post="Circul. Physiol.300, H555â€&quot;H564. 10.1152/ajpheart.00847.201021112947 YamamotoK.OhishiM.KatsuyaT.ItoN.IkushimaM.KaibeM.et al.. (2006). Deletion of"/>
 <result pre="by increasing local angiotensin II. Hypertension47, 718â€&quot;726. 10.1161/01.HYP.0000205833.89478.5b16505206 YanR.ZhangY.LiY.XiaL.GuoY.ZhouQ. (2020)." exact="Structural" post="basis for the recognition of SARS-CoV-2 by full-length human"/>
 <result pre="al.. (2020). Clinical course and risk factors for mortality of" exact="adult" post="inpatients with COVID-19 in Wuhan, China: a retrospective cohort"/>
 <result pre="glucose control and outcomes in patients with COVID-19 and pre-existing" exact="type 2" post="diabetes. Cell Metab. 10.1016/j.cmet.2020.04.021. [Epub ahead of print]. 32369736"/>
</results>
